1
|
Vanjak A, Garzaro M, Knapp S, Silvestrini MA, Martin de Fremont G, Bertinchamp R, Calvani J, Meignin V, Dossier A, Galicier L, Oksenhendler E, Boutboul D. Reply to Zhou et al. 'A novel approach for characterization of KSHV-associated multicentric Castleman disease from effusions'. Br J Haematol 2023; 201:357-359. [PMID: 36786160 DOI: 10.1111/bjh.18698] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2023] [Accepted: 02/02/2023] [Indexed: 02/15/2023]
Affiliation(s)
- Anthony Vanjak
- INSERM U976 HIPI, équipe INSIGHT, Institut de Recherche Saint Louis, Université Paris Cité, Paris, France
| | - Margaux Garzaro
- INSERM U976 HIPI, équipe INSIGHT, Institut de Recherche Saint Louis, Université Paris Cité, Paris, France
| | - Silene Knapp
- INSERM U976 HIPI, équipe INSIGHT, Institut de Recherche Saint Louis, Université Paris Cité, Paris, France
| | - Marc-Antoine Silvestrini
- INSERM U976 HIPI, équipe INSIGHT, Institut de Recherche Saint Louis, Université Paris Cité, Paris, France
| | - Gregoire Martin de Fremont
- INSERM U976 HIPI, équipe INSIGHT, Institut de Recherche Saint Louis, Université Paris Cité, Paris, France
| | - Remi Bertinchamp
- Clinical Immunology Department, Hôpital Saint Louis, Université Paris Cité, Paris, France
| | - Julien Calvani
- Pathology Department, Hôpital Saint Louis, Université Paris Cité, Paris, France
| | - Véronique Meignin
- Pathology Department, Hôpital Saint Louis, Université Paris Cité, Paris, France
| | - Antoine Dossier
- Internal Medicine Department, Hôpital Bichat, Université Paris Cité, Paris, France
| | - Lionel Galicier
- Clinical Immunology Department, Hôpital Saint Louis, Université Paris Cité, Paris, France.,National Reference Center for Castleman disease, Hôpital Saint Louis, Université Paris Cité, Paris, France
| | - Eric Oksenhendler
- Clinical Immunology Department, Hôpital Saint Louis, Université Paris Cité, Paris, France.,National Reference Center for Castleman disease, Hôpital Saint Louis, Université Paris Cité, Paris, France
| | - David Boutboul
- INSERM U976 HIPI, équipe INSIGHT, Institut de Recherche Saint Louis, Université Paris Cité, Paris, France.,Clinical Immunology Department, Hôpital Saint Louis, Université Paris Cité, Paris, France.,National Reference Center for Castleman disease, Hôpital Saint Louis, Université Paris Cité, Paris, France
| |
Collapse
|
2
|
Bertinchamp R, Terriou L. Maladies de Castleman : épidémiologie, classification et critères diagnostiques. Rev Med Interne 2022; 43:10S4-10S9. [PMID: 36657941 DOI: 10.1016/s0248-8663(23)00019-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Castleman disease is a group of rare disorders characterized by lymph node enlargement, specific microscopic changes to the lymph nodes, and a broad range of symptoms and laboratory findings. The two main subtypes are unicentric Castleman disease (UCD) and multicentric Castleman disease (MCD). The multicentric subtype can be further classified into two categories: HHV-8 positive multicentric Castleman disease and idiopathic multicentric Castleman disease (iMCD). In the United States (US), the annual incidence of Castleman disease (CD) has been estimated to range from 6500 to 7700 in a 2014 study. Approximately 75 percent were estimated to be unicentric CD and the remaining 25 percent were estimated to be split between HHV-8-associated MCD or HHV-8-negative/idiopathic MCD. Diagnostic criteria for iMCD have been established by an international working group of pediatric and adult pathology and clinical experts. The proposed consensus criteria require characteristic histopathologic findings on lymph node biopsy, enlargement of multiple lymph node regions, the presence of multiple clinical and laboratory abnormalities, and the exclusion of infectious, malignant, and autoimmune disorders that can mimic iMCD. © 2022 Published by Elsevier Masson SAS on behalf of Société nationale française de médecine interne (SNFMI).
Collapse
Affiliation(s)
- R Bertinchamp
- Service de médecine interne et immunologie clinique, CHU Antoine-Béclère, Clamart, France.
| | - L Terriou
- Service de médecine interne et immunologie clinique, Centre de référence des maladies auto-immunes systémiques rares du nord et nord-ouest de France (CeRAINO), CHU de Lille, Lille, France
| |
Collapse
|
3
|
Calvani J, Gérard L, Fadlallah J, Poullot E, Galicier L, Robe C, Garzaro M, Bertinchamp R, Boutboul D, Cuccuini W, Cayuela JM, Gaulard P, Oksenhendler É, Meignin V. A Comprehensive Clinicopathologic and Molecular Study of 19 Primary Effusion Lymphomas in HIV-infected Patients. Am J Surg Pathol 2022; 46:353-362. [PMID: 34560683 DOI: 10.1097/pas.0000000000001813] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Primary effusion lymphoma (PEL) is associated with human herpesvirus 8 and frequently with Epstein-Barr virus (EBV). We report here a single-center series of 19 human immunodeficiency virus-associated PELs, including 14 EBV+ and 5 EBV- PELs. The objectives were to describe the clinicopathologic features of PELs, with a focus on programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) expression, to search for genetic alterations by targeted deep sequencing analysis, and to compare the features between EBV+ and EBV- cases. All the patients were male, and the median age at diagnosis was 47 years old (interquartile range: 40 to 56 y). Reflecting the terminal B-cell differentiation, immunophenotypic profiles showed low expression levels of B-cell markers, including CD19 (0/19), CD20 (1/19), CD79a (0/19), PAX5 (1/19), BOB1 (3/19), and OCT2 (4/19), contrasting with a common expression of CD38 (10/19), CD138 (7/19), and IRF4/MUM1 (18/19). We observed a frequent aberrant expression of T-cell markers, especially CD3 (10/19), and less frequently CD2 (2/19), CD4 (3/19), CD5 (1/19), and CD8 (0/19). Only 2 cases were PD-L1 positive on tumor cells and none PD-1 positive. With respect to immune cells, 3 samples tested positive for PD-L1 and 5 for PD-1. Our 36-gene lymphopanel revealed 7 distinct variants in 5/10 PELs, with either a single or 2 mutations per sample: B2M (n=2), CD58 (n=1), EP300 (n=1), TNFAIP3 (n=1), ARID1A (n=1), and TP53 (n=1). Finally, we did not observe any major clinical, pathologic, or immunohistochemical differences between EBV+ and EBV- PELs and the outcome was similar (2-y overall survival probability of 61.9% [95% confidence interval, 31.2-82.1] vs. 60.0% [95% confidence interval, 12.6-88.2], respectively, P=0.62).
Collapse
Affiliation(s)
| | | | | | - Elsa Poullot
- Department of Pathology, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP)
- INSERM U955, University Paris-Est Créteil, Créteil, France
| | | | - Cyrielle Robe
- Department of Pathology, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP)
- INSERM U955, University Paris-Est Créteil, Créteil, France
| | | | | | | | | | - Jean-Michel Cayuela
- Hematology Laboratory, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP)
- University of Paris, Paris
| | - Philippe Gaulard
- Department of Pathology, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP)
- INSERM U955, University Paris-Est Créteil, Créteil, France
| | | | | |
Collapse
|
4
|
Morin G, Mageau A, Benali K, Bertinchamp R, Piekarski E, Raimbourg Q, Alexandra JF, Goulenok T, van Gysel D, Papo T, Sacre K. Persistent FDG/PET CT uptake in idiopathic retroperitoneal fibrosis helps identifying patients at a higher risk for relapse. Eur J Intern Med 2019; 62:67-71. [PMID: 30711361 DOI: 10.1016/j.ejim.2019.01.019] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/26/2018] [Revised: 01/10/2019] [Accepted: 01/30/2019] [Indexed: 12/20/2022]
Abstract
BACKGROUND The aim of this study was to evaluate the prognostic value of persistent retroperitoneal fibrosis FDG uptake using FDG/PET CT in patients with idiopathic retroperitoneal fibrosis (IRF). METHODS In this monocentric retrospective cohort study, all patients admitted for IRF from January 2009 to December 2017 underwent a FDG/PET CT at diagnosis and during follow up. Metabolic activity of IRF was assessed by retroperitoneal fibrosis FDG uptake measured as maximal standardized uptake value (SUVmax). The primary outcome was IRF relapse rate during follow-up. RESULTS 23 consecutive patients (54.7 [36.9-89] years, 73.9% of men) diagnosed with IRF had FDG/PET CT imaging performed at diagnosis, 3.1 [1-8.7] months (i.e 1st evaluation) and 10.4 [4.9-17.5] months (i.e 2nd evaluation) after diagnosis. High FDG retroperitoneal fibrosis uptake was present in all patients at diagnosis (SUVmax 6.5 [3.8-11.9]) and persisted in 16 (69.6%; SUVmax 3.65 [2.1-5.4]) and 12 (52.2%; SUVmax 3.75 [2.7-7.8]) patients, at 1st and 2nd evaluation respectively. All but one patient had received steroids at IRF diagnosis and 21 (91.3%) were in complete remission at both 1st and 2nd evaluation. During a median follow-up period of 38.7 [3-106.9] months, 6 (26.1%) patients suffered IRF relapse that occurred 15.7 [9.2-42.8] months after diagnosis. Multivariate analysis showed that only persistent retroperitoneal fibrosis FDG uptake at 2nd evaluation was associated with IRF relapse (p = .046). CONCLUSIONS In IRF, persistent retroperitoneal fibrosis FDG uptake during follow up is associated with clinical outcome. FDG/PET CT may help to better stratify the risk of relapse and target therapy in IRF.
Collapse
Affiliation(s)
- Gabriel Morin
- Département de Médecine Interne, Hôpital Bichat, PRES Sorbonne Paris Cité, Assistance Publique Hôpitaux de Paris, Université Paris Diderot, Paris, France
| | - Arthur Mageau
- Département de Médecine Interne, Hôpital Bichat, PRES Sorbonne Paris Cité, Assistance Publique Hôpitaux de Paris, Université Paris Diderot, Paris, France
| | - Khadija Benali
- Département de Médecine Nucléaire, Hôpital Bichat, PRES Sorbonne Paris Cité, Assistance Publique Hôpitaux de Paris, Université Paris Diderot, Paris, France
| | - Remi Bertinchamp
- Département de Médecine Interne, Hôpital Bichat, PRES Sorbonne Paris Cité, Assistance Publique Hôpitaux de Paris, Université Paris Diderot, Paris, France
| | - Eve Piekarski
- Département de Médecine Nucléaire, Hôpital Bichat, PRES Sorbonne Paris Cité, Assistance Publique Hôpitaux de Paris, Université Paris Diderot, Paris, France
| | - Quentin Raimbourg
- Département de Nephrologie, Hôpital Bichat, PRES Sorbonne Paris Cité, Assistance Publique Hôpitaux de Paris, Université Paris Diderot, Paris, France
| | - Jean-Francois Alexandra
- Département de Médecine Interne, Hôpital Bichat, PRES Sorbonne Paris Cité, Assistance Publique Hôpitaux de Paris, Université Paris Diderot, Paris, France
| | - Tiphaine Goulenok
- Département de Médecine Interne, Hôpital Bichat, PRES Sorbonne Paris Cité, Assistance Publique Hôpitaux de Paris, Université Paris Diderot, Paris, France
| | - Damien van Gysel
- Département d'Information Médicale, Hôpital Bichat, PRES Sorbonne Paris Cité, Assistance Publique Hôpitaux de Paris, Université Paris Diderot, Paris, France
| | - Thomas Papo
- Département de Médecine Interne, Hôpital Bichat, PRES Sorbonne Paris Cité, Assistance Publique Hôpitaux de Paris, Université Paris Diderot, Paris, France; Département Hospitalo-Universitaire FIRE (Fibrosis, Inflammation and Remodelling in Renal and Respiratory Diseases), Paris, France; INSERM U1149, Paris, France
| | - Karim Sacre
- Département de Médecine Interne, Hôpital Bichat, PRES Sorbonne Paris Cité, Assistance Publique Hôpitaux de Paris, Université Paris Diderot, Paris, France; Département Hospitalo-Universitaire FIRE (Fibrosis, Inflammation and Remodelling in Renal and Respiratory Diseases), Paris, France; INSERM U1149, Paris, France.
| |
Collapse
|
5
|
Lafarge A, Bertinchamp R, Pichereau C, Valade S, Chermak A, Theodose I, Canet E, Lemiale V, Schlemmer B, Galicier L, Azoulay E, Mariotte E. Prognosis of autoimmune hemolytic anemia in critically ill patients. Ann Hematol 2018; 98:589-594. [PMID: 30536106 DOI: 10.1007/s00277-018-3553-9] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2018] [Accepted: 08/14/2018] [Indexed: 11/28/2022]
Abstract
Patients with autoimmune hemolytic anemia (AIHA) may require intensive care unit (ICU) admission. In order to describe the characteristics of AIHA patients in ICU and identify prognosis factors, clinical and biological data from 44 patients admitted in one ICU between 2002 and 2015 were retrospectively analyzed. The main reasons for ICU admission were profound anemia without any organ failure in 19 patients (either for safer transfusion or continuous monitoring only). Twenty-five (57%) patients had a past history of hemopathy. Twenty patients presented with a direct anti-globulin test (DAT) positive for immunoglobulin G (DAT-IgG) only (46%), 8 with a DAT positive for both IgG and complement (DAT-IgG+C) (36%), and 16 with a DAT positive for complement only (DAT-IgG+C) (18%). Corticosteroids and rituximab were administered to respectively 44 (100%) and 12 (25%) patients. Red blood cell transfusion was required in 28 (64%) patients. Ten (23%) patients received vasopressors. Renal replacement therapy was necessary in 14 (31.8%) patients. Thirteen (30%) patients died in the ICU. There was no difference between survivors and non-survivors regarding associated comorbidities like hemopathy (18/31 [58%] vs. 7/13 [54%], p = 0.80). In decedents, age was higher (72 years [57.8-76.3] vs. 50 years [34.3-64], p < 0.01) and organ dysfunctions were more severe at day 1 (SOFA 8 [7-11] vs. 5.5 [3-7], p < 0.01). Patients with a DAT-IgG displayed poorer outcome in comparison with patients with DAT-IgG+C/C (hospital mortality 69% vs. 36%, p = 0.04). Mortality rate of AIHA patients requiring ICU admission is consequential and appears to be impacted by age, organ failures, and DAT-IgG.
Collapse
Affiliation(s)
- Antoine Lafarge
- Medical Intensive Care Unit, Saint-Louis Teaching Hospital, AP-HP, Paris, France.
| | - R Bertinchamp
- Department of Clinical Immunology, Saint-Louis Teaching Hospital, AP-HP, Paris, France
| | - C Pichereau
- Medical Intensive Care Unit, Saint-Louis Teaching Hospital, AP-HP, Paris, France
| | - S Valade
- Medical Intensive Care Unit, Saint-Louis Teaching Hospital, AP-HP, Paris, France
| | - A Chermak
- Medical Intensive Care Unit, Saint-Louis Teaching Hospital, AP-HP, Paris, France
| | - I Theodose
- Medical Intensive Care Unit, Saint-Louis Teaching Hospital, AP-HP, Paris, France
| | - E Canet
- Medical Intensive Care Unit, Saint-Louis Teaching Hospital, AP-HP, Paris, France
| | - V Lemiale
- Medical Intensive Care Unit, Saint-Louis Teaching Hospital, AP-HP, Paris, France
| | - B Schlemmer
- Medical Intensive Care Unit, Saint-Louis Teaching Hospital, AP-HP, Paris, France
| | - L Galicier
- Department of Clinical Immunology, Saint-Louis Teaching Hospital, AP-HP, Paris, France
| | - E Azoulay
- Medical Intensive Care Unit, Saint-Louis Teaching Hospital, AP-HP, Paris, France
| | - E Mariotte
- Medical Intensive Care Unit, Saint-Louis Teaching Hospital, AP-HP, Paris, France
| |
Collapse
|
6
|
Roriz M, Alexandra J, Bertinchamp R, Chauveheid M, Cohen Aubart F, Doan S, Dossier A, Goulenok T, Klein I, Rouzaud D, Sacré K, Papo T. Syndrome de SUSAC : séquelles et absence de facteurs cliniques prédictifs. Rev Med Interne 2018. [DOI: 10.1016/j.revmed.2018.10.370] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
7
|
Mahévas T, Bertinchamp R, Battistella M, Reygagne P, Oksenhendler E, Fieschi C, Bachelez H. Efficacy of oral sirolimus as salvage therapy in refractory lichen planus associated with immune deficiency. Br J Dermatol 2018; 179:771-773. [DOI: 10.1111/bjd.16555] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- T. Mahévas
- Dermatology Department; AP-HP Hôpital; Saint-Louis, Paris France
| | - R. Bertinchamp
- Clinical Immunology Department; AP-HP Hôpital; Saint-Louis, Paris France
| | - M. Battistella
- Pathology Department; AP-HP Hôpital; Saint-Louis, Paris France
- Sorbonne Paris Cité Université Paris Diderot; Paris France
| | - P. Reygagne
- Sabouraud Center; Saint-Louis Hospital; Paris France
| | - E. Oksenhendler
- Clinical Immunology Department; AP-HP Hôpital; Saint-Louis, Paris France
- Sorbonne Paris Cité Université Paris Diderot; Paris France
| | - C. Fieschi
- Clinical Immunology Department; AP-HP Hôpital; Saint-Louis, Paris France
- Sorbonne Paris Cité Université Paris Diderot; Paris France
| | - H. Bachelez
- Dermatology Department; AP-HP Hôpital; Saint-Louis, Paris France
- Sorbonne Paris Cité Université Paris Diderot; Paris France
- UMR INSERM 1163; Institut Imagine; Hôpital Necker; Paris France
| |
Collapse
|
8
|
Birsen R, Boutboul D, Crestani B, Seguin-Givelet A, Fieschi C, Bertinchamp R, Giol M, Malphettes M, Oksenhendler E, Galicier L. Talc pleurodesis allows long-term remission in HIV-unrelated Human Herpesvirus 8-associated primary effusion lymphoma. Leuk Lymphoma 2017; 58:1993-1998. [PMID: 28084853 DOI: 10.1080/10428194.2016.1271947] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Affiliation(s)
- Rudy Birsen
- a Department of Clinical Immunology , Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris (APHP) , Paris , France
| | - David Boutboul
- a Department of Clinical Immunology , Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris (APHP) , Paris , France.,b Inserm U1126, Centre Hayem, Hôpital Saint-Louis , Paris , France
| | - Bruno Crestani
- c Inserm U1152 , Université Paris Diderot Paris 7 , Paris , France.,d Department of Pneumology , Hôpital Bichat, Assistance Publique Hôpitaux de Paris (APHP) , Paris , France
| | - Agathe Seguin-Givelet
- e Department of Thoracic and Vascular Surgery , Hôpital Avicenne, Assistance Publique Hôpitaux de Paris (APHP) , Paris , France.,f Faculté de médecine SMBH , Université Sorbonne Paris Cité, Université Paris 13 , Bobigny , France
| | - Claire Fieschi
- a Department of Clinical Immunology , Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris (APHP) , Paris , France.,b Inserm U1126, Centre Hayem, Hôpital Saint-Louis , Paris , France.,g EA3518, Université Paris Diderot Paris 7 , Paris , France
| | - Remi Bertinchamp
- a Department of Clinical Immunology , Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris (APHP) , Paris , France
| | - Mihaela Giol
- h Department of Thoracic Surgery , Hôpital Tenon, Assistance Publique Hôpitaux de Paris (APHP) , Paris , France
| | - Marion Malphettes
- a Department of Clinical Immunology , Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris (APHP) , Paris , France.,b Inserm U1126, Centre Hayem, Hôpital Saint-Louis , Paris , France
| | - Eric Oksenhendler
- a Department of Clinical Immunology , Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris (APHP) , Paris , France.,g EA3518, Université Paris Diderot Paris 7 , Paris , France
| | - Lionel Galicier
- a Department of Clinical Immunology , Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris (APHP) , Paris , France.,g EA3518, Université Paris Diderot Paris 7 , Paris , France
| |
Collapse
|